HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer Gives Consumer Health A Star, But Plans $1.76Bn In Annual Overall Cost Reductions

Executive Summary

Bayer notes “significant headwinds" from pandemic hitting its 2020 results likely will continue in 2021, when it t expects core earnings per share slightly below 2020 levels. While noting slumping revenues across its divisions, Bayer said an exception its consumer health business.

You may also be interested in...



Bayer Execs On Digital Acceleration, Getting The Building Blocks Right

Senior executives from Bayer outlined at a recent summit the contours of digital transformation already underway and the vital components of a successful digital team. Firms need to be able to operate technology at the “speed of business” and not “at the speed of a ticketing queue.”

Bayer Sees Positive Consumer Change From COVID-19 Despite Slowing Sales

Bayer says the growing interest in self-care triggered by the coronavirus outbreak is here to stay, with demand showing no sign of slowing for dietary supplements as consumers look to give their immune systems a boost. While Bayer benefited from this in the second quarter, sales across its other Consumer Health categories went into reverse as a result of lockdowns and social distancing measures. 

Bayer To Settle Monsanto Litigation, Remains Prepared To Invest For Growth

The health care and crop science conglomerate will pay up to $10.9bn to resolve most Roundup claims, but still has capital to do bolt-on deals like last year’s BlueRock cell therapy buy.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1122620

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel